MedPath

A prospective feasibility study of allogeneic hematopoietic stem cell transplantation using once daily intravenous busulfan and fludarabine as conditioning regime

Not Applicable
Conditions
hematological malignancy
Registration Number
JPRN-UMIN000029115
Lead Sponsor
Osaka International Cancer Institute
Brief Summary

Because the new treatment schedule was approved by the government, we stopped the study which assessed the feasibility of the same schedule of administration.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
0
Inclusion Criteria

Not provided

Exclusion Criteria

No exclusion criteria

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath